Other Information.
+Added: On May 11, 2022, the Company and Penn entered into an amendment to the Penn Agreement pursuant to which the Company returned to Penn the rights to the Canavan disease, Charcot-Marie-Tooth Type 2A and Parkinson’s disease research programs.
+Added: The amendment did not result in any termination costs.
The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index below.
Filed/Furnished
−Removed: Fifth Amendment to Amended and Restated Research, License & Collaboration Agreement, dated August 3, 2021, by and between the Registrant and the Trustees of the University of Pennsylvania
−Removed: Employment Agreement, dated August 23, 2021, by and between the Registrant and Simona King.
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
22 unchanged sentences
PASSAGE BIO, INC.
−Removed: November 4, 2021
/s/ Bruce Goldsmith
1 unchanged sentence
Chief Executive Officer and President
−Removed: November 4, 2021
/s/ Simona King
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.